Foster City, CA, United States of America

Mouhannad Jamaa

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Mouhannad Jamaa in Liposomal Compositions

Introduction

Mouhannad Jamaa is an accomplished inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of liposomal compositions that enhance the therapeutic efficacy of peptide epoxyketone compounds.

Latest Patents

Mouhannad Jamaa holds a patent for "Liposomal compositions of epoxyketone-based proteasome inhibitors." This patent describes liposomal compositions comprising peptide epoxyketone compounds, along with methods for their production and application. The innovation focuses on improving the in vivo half-life of these compounds compared to non-liposomal alternatives. The liposomal compositions not only provide desirable pharmacodynamic profiles but also demonstrate anti-tumor activity in human tumor xenograft models, surpassing the effectiveness of non-liposomal compositions. Furthermore, the experiments supporting this invention indicate improved tolerability of the liposomal formulations.

Career Highlights

Mouhannad Jamaa is currently associated with Onyx Therapeutics, Inc., where he continues to advance his research and development efforts. His work has been pivotal in enhancing the therapeutic window of peptide epoxyketone compounds, contributing to the field of oncology.

Collaborations

Mouhannad has collaborated with notable colleagues, including Katherine A Chu and Elena T Chan. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of therapeutic solutions.

Conclusion

Mouhannad Jamaa's contributions to the field of liposomal compositions represent a significant advancement in cancer treatment methodologies. His innovative work continues to pave the way for improved therapeutic options in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…